Manganese

The N30 dog presentation is registered in Georgia (000894, valid to 2030) with the Argentine maker's leaflet, but no EU, UK or US authorisation was documented in the reviewed evidence or product study, and claims rest on manufacturer material.

Systematic reviews and pain guidelines find weak or inconsistent evidence that glucosamine and chondroitin improve pain or function in canine osteoarthritis; a fixed one tablet above 15 kg also gives large dogs a low dose per kg.

The manufacturer leaflet lists pregnancy, lactation and phenylketonuria exclusions and possible antibiotic-absorption interactions, but no exact-product tolerability study or quantified adverse-event dataset was found.

A palatable scored tablet once daily (half below 15 kg, one above) for at least 6 weeks is easy, but the leaflet leaves exactly 15 kg unassigned.

The N18 dog presentation is registered in Georgia (000892, valid to 2030) with the Argentine maker's leaflet; carprofen itself is EU-authorised for dogs with strong independent evidence, but this fixed combination has no EU, UK or US authorisation documented in the reviewed evidence or product study.

Carprofen reliably reduces osteoarthritis pain and inflammation in dogs; the glucosamine and chondroitin add no proven benefit, least of all over an 8-day course.

Weight bands give up to about 9 mg/kg carprofen at 3 kg and about 7 mg/kg at 8 kg, roughly double the usual 4 mg/kg daily dose; NSAID gastrointestinal, renal and hepatic risks apply and the leaflet leaves dose gaps at 7.5-8 kg and 15 kg.

A palatable scored tablet once daily is easy to give, but quarter-tablet splitting and coarse bands make accurate dosing hard in small dogs.